Fate Therapeutics (FATE) Competitors $0.96 -0.04 (-3.77%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$0.96 0.00 (-0.24%) As of 09/19/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FATE vs. ERAS, PRTA, ZYBT, ZVRA, CRVS, CYRX, SLDB, ATXS, KMDA, and INBXShould you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Erasca (ERAS), Prothena (PRTA), Zhengye Biotechnology (ZYBT), Zevra Therapeutics (ZVRA), Corvus Pharmaceuticals (CRVS), CryoPort (CYRX), Solid Biosciences (SLDB), Astria Therapeutics (ATXS), Kamada (KMDA), and Inhibrx Biosciences (INBX). These companies are all part of the "pharmaceutical products" industry. Fate Therapeutics vs. Its Competitors Erasca Prothena Zhengye Biotechnology Zevra Therapeutics Corvus Pharmaceuticals CryoPort Solid Biosciences Astria Therapeutics Kamada Inhibrx Biosciences Fate Therapeutics (NASDAQ:FATE) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings. Which has better earnings & valuation, FATE or ERAS? Erasca has lower revenue, but higher earnings than Fate Therapeutics. Erasca is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$13.63M8.14-$186.26M-$1.45-0.66ErascaN/AN/A-$161.65M-$0.45-4.09 Do insiders & institutionals believe in FATE or ERAS? 97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 5.5% of Fate Therapeutics shares are held by company insiders. Comparatively, 14.4% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts prefer FATE or ERAS? Fate Therapeutics presently has a consensus target price of $3.30, suggesting a potential upside of 242.93%. Erasca has a consensus target price of $3.71, suggesting a potential upside of 101.86%. Given Fate Therapeutics' higher probable upside, equities research analysts clearly believe Fate Therapeutics is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.14Erasca 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Does the media refer more to FATE or ERAS? In the previous week, Erasca had 1 more articles in the media than Fate Therapeutics. MarketBeat recorded 2 mentions for Erasca and 1 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 1.81 beat Erasca's score of 0.24 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Erasca 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is FATE or ERAS more profitable? Erasca has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,025.05%. Erasca's return on equity of -31.19% beat Fate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-2,025.05% -50.95% -36.76% Erasca N/A -31.19%-26.34% Which has more risk & volatility, FATE or ERAS? Fate Therapeutics has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. Comparatively, Erasca has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. SummaryErasca beats Fate Therapeutics on 9 of the 15 factors compared between the two stocks. Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FATE vs. The Competition Export to ExcelMetricFate TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$110.98M$3.15B$5.79B$10.47BDividend YieldN/A2.36%5.61%4.61%P/E Ratio-0.6620.9180.5026.80Price / Sales8.14460.07532.45123.16Price / CashN/A46.4637.6661.43Price / Book0.349.6015.756.39Net Income-$186.26M-$53.22M$3.30B$271.80M7 Day Performance-0.08%3.11%5.36%3.49%1 Month Performance-14.84%7.56%8.10%9.90%1 Year Performance-75.13%11.15%81.36%28.62% Fate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FATEFate Therapeutics4.0043 of 5 stars$0.96-3.8%$3.30+242.9%-75.9%$110.98M$13.63M-0.66550Positive NewsERASErasca2.1114 of 5 stars$1.60+2.6%$3.71+132.1%-38.0%$442.52MN/A-3.56120PRTAProthena3.5432 of 5 stars$8.16-0.6%$19.75+142.0%-62.7%$441.94M$135.16M-1.45130ZYBTZhengye BiotechnologyN/A$10.69+14.7%N/AN/A$439.59M$25.53M0.00278ZVRAZevra Therapeutics2.7937 of 5 stars$7.23-6.7%$23.71+228.0%-4.4%$435.05M$23.61M0.0020CRVSCorvus Pharmaceuticals1.7067 of 5 stars$5.88+0.9%$15.00+155.1%+4.6%$434.42MN/A-5.8230Positive NewsCYRXCryoPort3.7269 of 5 stars$8.77+1.5%$12.00+36.8%+14.2%$432.58M$228.38M6.591,186News CoveragePositive NewsAnalyst ForecastSLDBSolid Biosciences2.7093 of 5 stars$5.49+1.9%$15.00+173.2%-36.0%$419.71M$8.09M0.00100ATXSAstria Therapeutics3.0938 of 5 stars$7.37-0.8%$29.00+293.5%-42.9%$419.31MN/A-3.6730News CoveragePositive NewsAnalyst ForecastKMDAKamada4.4691 of 5 stars$6.83-2.7%$13.00+90.3%+26.8%$403.68M$160.95M20.09360Positive NewsShort Interest ↓INBXInhibrx Biosciences1.1065 of 5 stars$27.18-1.2%N/A+57.8%$398.64M$200K0.00166Positive News Related Companies and Tools Related Companies Erasca Alternatives Prothena Alternatives Zhengye Biotechnology Alternatives Zevra Therapeutics Alternatives Corvus Pharmaceuticals Alternatives CryoPort Alternatives Solid Biosciences Alternatives Astria Therapeutics Alternatives Kamada Alternatives Inhibrx Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FATE) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FATE Stock Alerts